At present, the most well-established AD biomarkers are mainly based on the core pathological features, including amyloid β (Aβ) deposition [detected by cerebrospinal fluid (CSF)] Aβ42 levels, amyloid positron emission tomography (PET), neurodegeneration [CSF total tau (t-tau)] and phosphorylated (p)-tau levels, structural MRI, and hypometabolism on fluorodeoxyglucose (FDG)-PET (Desikan et al., 2009; Mattsson et al., 2009; Landau et al., 2012). This evidence concerns the gene MAPT and Alzheimer disease.